Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Urology
•
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Infectious Disease
How do you approach management of DMARDs and biologics in a patient with active RA, but frequent recurrent simple UTIs?
Related Questions
Do you routinely consider FDG PET/CT imaging for workup of fever of unknown origin?
Do you find HZV titers useful in diagnosing shingles sine herpete?
How do you approach treatment intensification in patients with RA and low disease activity but not in remission, considering the potential risks of increased immunosuppression?
How often do you see bony erosions in patients with Lyme arthritis?
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?
What is the maximum dose of leucovorin that you use with methotrexate?
Is there a risk of hepatitis C activation with rituximab in a patient who has a history of HCV treated with antivirals and who is in sustained viral response?
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
What is the interpretation of an IGRA with positive TB wells and negative nil and negative mitogen wells?
What isolation policies are Rheumatology offices employing for both staff and patients diagnosed with COVID-19 given the new CDC guidelines?
